These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26607)

  • 41. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 42. Treatment of parkinsonism.
    Calne DB; Teychenne PF; Pfeiffer RF
    Adv Exp Med Biol; 1977; 90():49-61. PubMed ID: 930750
    [No Abstract]   [Full Text] [Related]  

  • 43. [Current views on the pathogenesis and pharmacotherapy of Parkinson disease].
    Kostowski W
    Neurol Neurochir Pol; 1987; 21(6):541-7. PubMed ID: 2835696
    [No Abstract]   [Full Text] [Related]  

  • 44. Alterations in dopamine receptors: effect of lesion and haloperidol treatment.
    Goldstein M; Lew JY; Asano T; Ueta K
    Commun Psychopharmacol; 1980; 4(1):21-5. PubMed ID: 6105037
    [No Abstract]   [Full Text] [Related]  

  • 45. [Experimental and clinical study on the dopaminergic receptor stimulating agents (author's transl)].
    Ohmoto T; Miyamoto T; Baba Y
    No To Shinkei; 1977 Jul; 29(7):?31-40. PubMed ID: 409419
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of Parkinson disease].
    Uono M
    Nihon Naika Gakkai Zasshi; 1982 Sep; 71(9):1217-22. PubMed ID: 6818313
    [No Abstract]   [Full Text] [Related]  

  • 47. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
    Elsworth JD; Roth RH
    Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antipsychotic and antidyskinetic properties of ergot dopamine agonists.
    Tamminga CA
    Adv Biochem Psychopharmacol; 1980; 23():397-403. PubMed ID: 7395624
    [No Abstract]   [Full Text] [Related]  

  • 49. The pharmacology of ergots: past and present.
    Lemberger L
    Fed Proc; 1978 Jun; 37(8):2176-80. PubMed ID: 26605
    [No Abstract]   [Full Text] [Related]  

  • 50. Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
    Poirier LJ
    Confin Neurol; 1974; 36(4-6):223-36. PubMed ID: 4218801
    [No Abstract]   [Full Text] [Related]  

  • 51. Letter: Bromocriptine in parkinsonism.
    Debono AG; Donaldson I; Marsden CD; Parkes JD
    Lancet; 1975 Nov; 2(7942):987-8. PubMed ID: 53479
    [No Abstract]   [Full Text] [Related]  

  • 52. Animal models of parkinsonism.
    Silbergeld EK; Calne DB
    Pharmacol Ther; 1981; 12(1):159-66. PubMed ID: 7271971
    [No Abstract]   [Full Text] [Related]  

  • 53. Idiopathic parkinsonism treated with bromocriptine.
    Teychenne PF; Leigh PN; Reid JL; Calne DB; Greenacre JK; Petrie A; Bamji AN
    Lancet; 1975 Sep; 2(7933):473-6. PubMed ID: 51285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bromocriptine in Parkinsonism.
    Calne DB; Teychenne PF; Claveria LE; Eastman R; Greenacre JK; Petrie A
    Br Med J; 1974 Nov; 4(5942):442-4. PubMed ID: 4425916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Depletion of dopamine in the striatum as an experimental model of Parkinsonism: direct effects and adaptive mechanisms.
    Schultz W
    Prog Neurobiol; 1982; 18(2-3):121-66. PubMed ID: 6813911
    [No Abstract]   [Full Text] [Related]  

  • 56. Ergot alkaloids and cyclic nucleotides in the CNS.
    Trabucchi M; Hofmann M; Montefusco O; Spano PF
    Pharmacology; 1978; 16 Suppl 1():150-55. PubMed ID: 205889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ergot derivatives for Parkinsonism.
    Calne DB; Williams AC; Nutt JG; Neophytides A; Eisler T; Teychenne PF
    Med J Aust; 1978 Nov; 2(3 Suppl):25-6. PubMed ID: 34083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum growth hormone response to bromocriptine during a glucose tolerance test in acromegaly.
    Cassar J; Mashiter K; Sullivan G; Joplin GF
    Acta Endocrinol (Copenh); 1976 May; 82(1):39-46. PubMed ID: 946714
    [No Abstract]   [Full Text] [Related]  

  • 59. The antiparkinsonian efficacy of bromocriptine.
    Lieberman A; Zolfaghari M; Boal D; Hassouri H; Vogel B; Battista A; Fuxe K; Goldstein M
    Neurology; 1976 May; 26(5):405-9. PubMed ID: 817221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Studies on the antiparkinsonism efficacy of lergotrile.
    Lieberman A; Miyamoto T; Battista AF; Goldstein M
    Neurology; 1975 May; 25(5):459-62. PubMed ID: 166332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.